Arcus Biosciences, Inc. (RCUS) Institutional Ownership

Ownership Summary

Arcus Biosciences, Inc. (NYSE:RCUS) has 202 institutional investors that have filed 13F reports for the period ending December 2025.

• Their combined ownership stood at 113.0% of outstanding shares in December 2025, up from 96.4% in September 2025.
• Their total shares held in RCUS increased 22.58% quarter over quarter, and separately, investors owning Arcus Biosciences increased 9.19% from a year ago.
• Of these 202 funds, 138 grew their exposure to Arcus Biosciences, 39 cut back, and 25 maintained positions.
• The aggregate institutional position in Arcus Biosciences amounted to 120.38Mn shares as of December 2025, up by 22.17Mn shares quarter on quarter, and up 35.55Mn shares year over year.
• Gilead Sciences, Inc. leads ownership in RCUS with 31.42Mn shares as of December 31, 2025, equal to 29.51% of outstanding shares.
• The largest buyers of Arcus Biosciences for the quarter ending December 2025 were VANGUARD PORTFOLIO MANAGEMENT LLC (4.27Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.86Mn), CITADEL ADVISORS LLC (1.23Mn), Parkman Healthcare Partners LLC (1.21Mn), Logos Global Management LP (1.2Mn).
• The largest sales of RCUS for the quarter ending December 2025 came from Point72 Asset Management, L.P. (3.15Mn), Goldman Sachs Group Inc (1.34Mn), Barclays Plc (1.04Mn), Caption Management, LLC (751.66K), JACOBS LEVY EQUITY MANAGEMENT, INC (499.64K).
• Arcus Biosciences's 10 largest shareholders as of December 2025 include Gilead Sciences, Inc. (31.42Mn), BlackRock, Inc. (15.23Mn), WELLINGTON MANAGEMENT GROUP LLP (6.09Mn), State Street Corp (5.41Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (5.03Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (4.27Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.86Mn), Woodline Partners LP (3.78Mn), MARSHALL WACE, LLP (3.76Mn), Siren, L.L.C. (3.01Mn) per Business Quant data.